APL-103 (EGFRi)

APL-103: Epidermal Growth Factor Receptor Inhibitor

APL-103 is a covalent, irreversible, mutant-selective epidermal growth factor receptor inhibitor (EGFRi) that has nanomolar inhibitory potency against EGFR (L858R, ex19del) and EGFR T790M. Preclinical data suggest that APL-103 is able to cross the blood brain barrier.

Epidermal growth factor receptor is the protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor. An EGFR inhibitor is a substance that blocks the activity of the EGFR protein and is designed to keep cancer cells from growing.

Apollomics retains worldwide rights to APL-103 outside of China.

Clinical Trials

The first planned clinical trial withAPL-103 will evaluate the asset in combination with Apollomicsc-Met inhibitor APL-101

Trial Details
Trial Name: APOLLO-2
Agents: APL-101 + APL-103 (EGFR inhibitor)
Indication: TBA

Clinical Partner & Clinical Trials:

Zhejiang Bossan Pharmaceutical Co., Ltd. has development rights in China for APL-103 where it is referred to as ES-072.